Vor shares new data for stem cell therapy; Melinta partners with Venatorx on antibiotic under FDA review
Plus, news about BeiGene, Zymeworks, Rznomics, and Adicet:
Vor Bio shares early data for its gene-edited stem cell therapy: The company announced Thursday that its stem cell treatment seemed to engraft normally in seven patients with acute myeloid leukemia (AML) treated so far. Three patients who received Mylotarg — Pfizer’s AML drug — saw “protection from deep cytopenias,” or a steep drop in blood cell counts that’s often seen as a side effect of the drug. Mylotarg targets CD33, an antigen found in high levels on leukemia cells but also expressed in some normal cells. Vor, founded on research led by Siddhartha Mukherjee, edits CD33 out of donor stem cells with the goal of sparing patients from the treatment’s side effects. More data are set to be presented at ASH, the company announced last week. — Lei Lei Wu
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.